JP2011510076A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011510076A5 JP2011510076A5 JP2010544340A JP2010544340A JP2011510076A5 JP 2011510076 A5 JP2011510076 A5 JP 2011510076A5 JP 2010544340 A JP2010544340 A JP 2010544340A JP 2010544340 A JP2010544340 A JP 2010544340A JP 2011510076 A5 JP2011510076 A5 JP 2011510076A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- modified polypeptide
- polypeptide according
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 54
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 49
- 229920001184 polypeptide Polymers 0.000 claims description 38
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 10
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 8
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 239000004215 Carbon black (E152) Substances 0.000 claims description 6
- 229930195733 hydrocarbon Natural products 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 241000711950 Filoviridae Species 0.000 claims 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims 1
- 108010072476 SIV envelope protein gp41 Proteins 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- CYNVQWNFIFUJRX-ICEZVUAISA-N chembl427630 Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 CYNVQWNFIFUJRX-ICEZVUAISA-N 0.000 claims 1
- 238000002983 circular dichroism Methods 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 16
- 108090000317 Chymotrypsin Proteins 0.000 description 4
- 102000057297 Pepsin A Human genes 0.000 description 4
- 108090000284 Pepsin A Proteins 0.000 description 4
- 229960002376 chymotrypsin Drugs 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 229940111202 pepsin Drugs 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000017960 syncytium formation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6200708P | 2008-01-23 | 2008-01-23 | |
| US61/062,007 | 2008-01-23 | ||
| PCT/US2009/000438 WO2009108261A2 (en) | 2008-01-23 | 2009-01-23 | Compositions and methods for the treatment of viral infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011510076A JP2011510076A (ja) | 2011-03-31 |
| JP2011510076A5 true JP2011510076A5 (https=) | 2012-03-08 |
| JP5788178B2 JP5788178B2 (ja) | 2015-09-30 |
Family
ID=41016644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010544340A Expired - Fee Related JP5788178B2 (ja) | 2008-01-23 | 2009-01-23 | ウィルス感染症の治療のための組成物及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US9290545B2 (https=) |
| EP (1) | EP2247606B1 (https=) |
| JP (1) | JP5788178B2 (https=) |
| CA (1) | CA2713089C (https=) |
| WO (1) | WO2009108261A2 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| CA2822302A1 (en) | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Methods of impairing osteoclast differentiation |
| US8937154B2 (en) | 2006-10-05 | 2015-01-20 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
| EP2073829B1 (en) * | 2006-10-05 | 2012-06-20 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
| WO2009110952A2 (en) | 2007-12-31 | 2009-09-11 | New York University | Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices |
| EP2247606B1 (en) | 2008-01-23 | 2019-08-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the treatment of viral infections |
| WO2009137532A1 (en) | 2008-05-06 | 2009-11-12 | New York Blood Center | Antiviral cell penetrating peptides |
| CA2737922A1 (en) | 2008-09-22 | 2010-03-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| BRPI0920899A2 (pt) | 2008-11-24 | 2016-04-26 | Aileron Therapeutics Inc | macrociclos peptidomiméticos com propriedades melhoradas |
| EP3549951A3 (en) | 2008-12-09 | 2019-11-20 | Dana Farber Cancer Institute, Inc. | Methods and compositions for specific modulation of mcl-1 |
| US9175047B2 (en) | 2009-01-14 | 2015-11-03 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| AU2010263056B2 (en) * | 2009-06-18 | 2016-01-07 | Dana Farber Cancer Institute, Inc. | Structured viral peptide compositions and methods of use |
| GB2471692A (en) * | 2009-07-08 | 2011-01-12 | Complix Nv | HIV gp41-binding single-chain coiled-coil peptide comprising heptad repeats |
| CA2817568A1 (en) | 2010-11-12 | 2012-05-18 | The Salk Institute For Biological Studies Intellectual Property And Tech Nology Transfer | Cancer therapies and diagnostics |
| WO2012083078A2 (en) * | 2010-12-15 | 2012-06-21 | The Research Foundation Of State University Of New York | Croos-linked peptides and proteins, methods of making same, and uses thereof |
| AU2012242502B2 (en) | 2011-04-15 | 2016-07-28 | Dana-Farber Cancer Institute, Inc. | Targeting deregulated WNT signaling in cancer using stabilized alpha-helices of BCL-9 |
| CA2862391C (en) * | 2011-12-29 | 2023-10-10 | Loren D. Walensky | Stabilized antiviral fusion helices |
| CN104203276A (zh) * | 2012-03-20 | 2014-12-10 | 默沙东公司 | Hiv-1 gp41前发夹中间物的稳定肽模拟物 |
| CN103483428B (zh) * | 2012-06-11 | 2017-05-17 | 中国人民解放军军事医学科学院毒物药物研究所 | 抑制hiv感染的小分子‑多肽缀合物 |
| HK1210192A1 (en) | 2012-07-19 | 2016-04-15 | Alethia Biotherapeutics Inc. | Anti-siglec-15 antibodies |
| EP2970418A4 (en) | 2013-03-15 | 2016-08-17 | Dana Farber Cancer Inst Inc | STABILIZED EZH2 PEPTIDES |
| AU2014227824B2 (en) | 2013-03-15 | 2018-09-27 | Dana-Farber Cancer Institute, Inc. | Stabilized SOS1 peptides |
| EP2970417B1 (en) | 2013-03-15 | 2019-06-19 | Dana-Farber Cancer Institute, Inc. | Bh4 stabilized peptides and uses thereof |
| US9644002B2 (en) | 2013-07-25 | 2017-05-09 | Yale University | Allosteric modulators of EGFR and constitutively active mutants |
| WO2015171924A2 (en) * | 2014-05-07 | 2015-11-12 | Cornell University | Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them |
| US10059741B2 (en) | 2015-07-01 | 2018-08-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| EP3317294B1 (en) | 2015-07-02 | 2023-03-15 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides |
| WO2017018595A1 (ko) * | 2015-07-28 | 2017-02-02 | 동국대학교 산학협력단 | 이중 스테이플화된 펩타이드 및 이의 용도 |
| US20190002506A1 (en) | 2015-08-28 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Stabilized peptides for covalent binding to target protein |
| CA2995479A1 (en) | 2015-08-28 | 2017-03-09 | Dana-Farber Cancer Institute, Inc. | Peptides binding to bfl-1 |
| CA3014442A1 (en) | 2016-02-29 | 2017-09-08 | Dana-Farber Cancer Institute, Inc. | Stapled intracellular-targeting antimicrobial peptides to treat infection |
| US11466064B2 (en) | 2016-08-26 | 2022-10-11 | Dana-Farber Cancer Institute, Inc. | Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss |
| WO2018106937A1 (en) | 2016-12-07 | 2018-06-14 | The University Of Chicago | Compositions and methods for inhibition of foxp3 |
| AU2018304230A1 (en) | 2017-07-19 | 2020-02-06 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections |
| AU2018329956A1 (en) | 2017-09-07 | 2020-08-20 | Fog Pharmaceuticals, Inc. | Agents modulating beta-catenin functions and methods thereof |
| US11865181B2 (en) | 2017-11-03 | 2024-01-09 | Yale University | Peptidic materials that traffic efficiently to the cell cytosol and nucleus |
| EP3737404A1 (en) | 2017-12-15 | 2020-11-18 | Dana Farber Cancer Institute, Inc. | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides |
| CN108822190B (zh) * | 2018-05-23 | 2021-11-09 | 中国人民解放军军事科学院军事医学研究院 | 多肽及其药物组合物和用途 |
| MX2021001943A (es) | 2018-08-20 | 2021-07-15 | Fog Pharmaceuticals Inc | Colecciones de péptidos, agentes peptídicos y métodos de uso de los mismos. |
| WO2021178714A2 (en) * | 2020-03-04 | 2021-09-10 | Dana-Farber Cancer Institute, Inc. | ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF |
| WO2021183463A1 (en) * | 2020-03-09 | 2021-09-16 | President And Fellows Of Harvard College | Compositions and methods for treating coronavirus |
| WO2021207517A2 (en) * | 2020-04-10 | 2021-10-14 | Sapience Therapeutics, Inc. | Modified hr2 peptide inhibitors of coronavirus fusion |
| CA3179872A1 (en) * | 2020-04-22 | 2021-10-28 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof |
| WO2022081711A1 (en) * | 2020-10-14 | 2022-04-21 | The Trustees Of Columbia University In The City Of New York | Lipopeptide fusion inhibitors as sars-cov-2 antivirals |
| CN116801908A (zh) * | 2020-10-14 | 2023-09-22 | 丹娜法伯癌症研究院 | 用于降解病毒和宿主蛋白的嵌合缀合物和使用方法 |
| US11479582B2 (en) | 2020-10-16 | 2022-10-25 | King Faisal University | Anti-SARS-CoV-2 fusion peptides |
| US20240002450A1 (en) * | 2020-11-05 | 2024-01-04 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized ebolavirus peptides and uses thereof |
| US20240052330A1 (en) * | 2020-12-22 | 2024-02-15 | The University Of Chicago | Blockade of sars-cov-2 infection using hydrocarbon stapled peptides |
| EP4453245A4 (en) * | 2021-12-23 | 2025-12-31 | Mammoth Biosciences Inc | DOSING IMPROVEMENTS BASED ON A PROGRAMMABLE NUCLEASE |
| WO2025167910A1 (zh) * | 2024-02-05 | 2025-08-14 | 中国人民解放军军事科学院军事医学研究院 | 一种可口服的长效多肽类hiv灭活剂 |
| WO2026024936A2 (en) | 2024-07-25 | 2026-01-29 | Dana-Farber Cancer Institute, Inc. | Bh4 domain peptides and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998020036A1 (en) | 1996-11-06 | 1998-05-14 | Genentech, Inc. | Constrained helical peptides and methods of making same |
| US6271198B1 (en) | 1996-11-06 | 2001-08-07 | Genentech, Inc. | Constrained helical peptides and methods of making same |
| CA2359892A1 (en) | 1999-01-08 | 2000-07-13 | Panacos Pharmaceuticals, Inc. | Methods of eliciting broadly neutralizing antibodies targeting hiv-1 gp41 |
| US20060241027A1 (en) * | 2002-02-07 | 2006-10-26 | Hans-Peter Hauser | Hiv inhibiting proteins |
| WO2004103312A2 (en) * | 2003-05-19 | 2004-12-02 | Progenics Pharmaceuticals, Inc. | Peptides useful as hiv fusion inhibitors |
| ES2586387T3 (es) | 2003-11-05 | 2016-10-14 | Dana-Farber Cancer Institute, Inc. | Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular |
| AU2004313242A1 (en) | 2004-01-07 | 2005-07-28 | Trimeris, Inc. | HIV gp41 HR2-derived synthetic peptides, and their use in therapy to inhibit transmission of human immunodeficiency virus |
| US8003332B2 (en) * | 2005-05-06 | 2011-08-23 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibition of membrane fusion proteins |
| CA2700892A1 (en) | 2007-09-26 | 2009-04-02 | Dana-Farber Cancer Institute, Inc. | Reagents for inducing an immune response |
| CA2700925C (en) * | 2007-09-26 | 2016-08-23 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
| EP2247606B1 (en) | 2008-01-23 | 2019-08-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the treatment of viral infections |
-
2009
- 2009-01-23 EP EP09715505.5A patent/EP2247606B1/en active Active
- 2009-01-23 JP JP2010544340A patent/JP5788178B2/ja not_active Expired - Fee Related
- 2009-01-23 CA CA2713089A patent/CA2713089C/en not_active Expired - Fee Related
- 2009-01-23 WO PCT/US2009/000438 patent/WO2009108261A2/en not_active Ceased
-
2010
- 2010-07-23 US US12/864,375 patent/US9290545B2/en not_active Expired - Fee Related
-
2016
- 2016-02-09 US US15/019,558 patent/US20160152667A1/en not_active Abandoned
- 2016-05-04 US US15/146,511 patent/US10259848B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011510076A5 (https=) | ||
| JP4925540B2 (ja) | ５−ヘリックスタンパク質 | |
| JP5788178B2 (ja) | ウィルス感染症の治療のための組成物及び方法 | |
| Root et al. | HIV-1 gp41 as a target for viral entry inhibition | |
| Ellis Dutch et al. | Virus membrane fusion proteins: biological machines that undergo a metamorphosis | |
| Weissenhorn et al. | Structural basis for membrane fusion by enveloped viruses | |
| JP3904553B2 (ja) | 抗融合性ペプチドの組換え産生方法 | |
| US20080269462A1 (en) | Peptide inhibitors of HIV entry | |
| Igonet et al. | SnapShot: Viral and eukaryotic protein fusogens | |
| Luo | The nucleocapsid of vesicular stomatitis virus | |
| US6858410B2 (en) | Process for making antifusogenic fusion peptides that form inclusion bodies | |
| Pérot et al. | From viruses to genes: syncytins | |
| AU2005225063B2 (en) | Peptide inhibitors of HIV entry | |
| Poumbourios et al. | Evolutionary conservation of the membrane fusion machine | |
| AU2001292944A1 (en) | Peptide inhibitors of HIV entry | |
| Gao | Peptide inhibitors targeting virus-cell fusion in class I enveloped viruses | |
| Kingsman et al. | Retroelement particles as purification, presentation and targeting vehicles | |
| Maillard et al. | Spectroscopic characterization of two peptides derived from the stem of rabies virus glycoprotein | |
| CN101724027A (zh) | 蛋白质三聚体化模序及其应用 | |
| Quinlan et al. | An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines | |
| Li et al. | Characterization of BIV Env core: implication for mechanism of BIV-mediated cell fusion | |
| Bianchi et al. | Covalent Trimeric Coiled Coils of the HIV gp41 HR1 Region are Extremely Potent and Broadly Neutralizing Inhibitors of Viral Infection | |
| WO2008112736A1 (en) | Tighter-binding c-peptide inhibitors of hiv-1 entry | |
| Dieckmann et al. | Structure and Dynamics in Viral RNA Packaging | |
| WO2003006056A2 (en) | End-locked five-helix protein |